Sanctuary Advisors LLC Takes Position in Haleon plc (NYSE:HLN)

Sanctuary Advisors LLC acquired a new stake in Haleon plc (NYSE:HLN - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 196,246 shares of the company's stock, valued at approximately $1,658,000.

Several other institutional investors and hedge funds have also modified their holdings of HLN. Cultivar Capital Inc. purchased a new stake in Haleon in the 2nd quarter valued at about $40,000. Allspring Global Investments Holdings LLC purchased a new stake in Haleon in the first quarter valued at approximately $43,000. GAMMA Investing LLC increased its position in Haleon by 151.3% during the first quarter. GAMMA Investing LLC now owns 6,106 shares of the company's stock worth $52,000 after purchasing an additional 3,676 shares during the last quarter. Pinnacle Bancorp Inc. raised its stake in Haleon by 29.8% during the first quarter. Pinnacle Bancorp Inc. now owns 6,188 shares of the company's stock worth $53,000 after purchasing an additional 1,421 shares during the period. Finally, Hexagon Capital Partners LLC boosted its holdings in shares of Haleon by 66.6% in the 2nd quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company's stock valued at $55,000 after purchasing an additional 2,677 shares during the last quarter. Hedge funds and other institutional investors own 6.67% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Berenberg Bank assumed coverage on Haleon in a report on Tuesday, August 6th. They set a "buy" rating for the company. UBS Group upgraded Haleon to a "strong-buy" rating in a report on Tuesday, October 1st. Morgan Stanley boosted their target price on Haleon from $9.90 to $10.95 and gave the stock an "overweight" rating in a report on Friday, September 20th. Finally, The Goldman Sachs Group downgraded shares of Haleon from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $10.95.

Haleon Stock Up 0.5 %

NYSE:HLN traded up $0.05 during mid-day trading on Thursday, hitting $10.12. The company had a trading volume of 4,341,025 shares, compared to its average volume of 5,138,891. The business has a fifty day simple moving average of $10.16 and a 200-day simple moving average of $9.07. The firm has a market capitalization of $46.21 billion, a price-to-earnings ratio of 33.73, a PEG ratio of 3.12 and a beta of 0.26. Haleon plc has a 1 year low of $7.70 and a 1 year high of $10.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Haleon (NYSE:HLN - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). Haleon had a return on equity of 13.15% and a net margin of 9.71%. The company had revenue of $3.50 billion for the quarter, compared to analyst estimates of $3.55 billion. During the same period last year, the firm posted $0.08 earnings per share. Equities analysts forecast that Haleon plc will post 0.47 earnings per share for the current fiscal year.

Haleon Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Thursday, September 19th. Stockholders of record on Friday, August 16th were paid a $0.0514 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a dividend yield of 1.6%. Haleon's dividend payout ratio (DPR) is presently 33.33%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.